Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.
Aashna KarbhariSherly MosessianKamaxi H TrivediFrank VallaMark JacobsonMark J TrutyNandakumar G PatnamDiane M SimeoneElcin ZanTracy BrennanHongli ChenPhillip H KuoKen HerrmannAjit H GoenkaPublished in: PloS one (2023)
@ClinicalTrials.gov identifier NCT05262855.
Keyphrases
- open label
- study protocol
- double blind
- phase iii
- locally advanced
- phase ii
- clinical trial
- pet imaging
- liver metastases
- phase ii study
- randomized controlled trial
- placebo controlled
- computed tomography
- pet ct
- positron emission tomography
- protein protein
- rectal cancer
- cross sectional
- squamous cell carcinoma
- radiation therapy
- binding protein
- amino acid
- small molecule
- wound healing